Catalog No. |
TD-HW632026 |
Species reactivity |
Human |
Applications |
Research Grade Biosimilar |
Host species |
Humanized |
Isotype |
IgG4-kappa |
Expression system |
Mammalian Cells |
Species |
Human |
Clonality |
Monoclonal |
Target |
IL13, NC30, Interleukin-13, IL-13 |
Endotoxin level |
Please contact with the lab for this information. |
Purity |
>95% as determined by SDS-PAGE. |
Purification |
Protein A/G purified from cell culture supernatant. |
Accession |
P35225 |
Form |
Liquid |
Storage buffer |
0.01M PBS, pH 7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
Alternate Names |
MILR1444A, PRO301444, CAS: 953400-68-5 |
Background |
Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases. |
Note |
For research use only. Not suitable for clinical or therapeutic use. |